These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9839592)

  • 21. [Role of neuroendocrine cells in prostate cancer progression].
    Sciarra A; Innocenzi M; Ravaziol M; Minisola F; Alfarone A; Cattarino S; Panebianco V; Buonocore V; Gentile V; Di Silverio F
    Urologia; 2011; 78(2):126-31. PubMed ID: 21574145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence.
    Ito T; Yamamoto S; Ohno Y; Namiki K; Aizawa T; Akiyama A; Tachibana M
    Oncol Rep; 2001; 8(6):1221-4. PubMed ID: 11605036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate.
    Angelsen A; Syversen U; Stridsberg M; Haugen OA; Mjølnerød OK; Waldum HL
    Prostate; 1997 May; 31(2):110-7. PubMed ID: 9140124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume.
    Ahlegren G; Pedersen K; Lundberg S; Aus G; Hugosson J; Abrahamsson P
    Urology; 2000 Dec; 56(6):1011-5. PubMed ID: 11113749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroendocrine cells and nerves in the prostate of the guinea pig: effects of peripheral denervation and castration.
    Acosta S; Dizeyi N; Pierzynowski S; Alm P; Abrahamsson PA
    Prostate; 2001 Feb; 46(3):191-9. PubMed ID: 11170147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma.
    Bollito E; Berruti A; Bellina M; Mosca A; Leonardo E; Tarabuzzi R; Cappia S; Ari MM; Tampellini M; Fontana D; Gubetta L; Angeli A; Dogliotti L
    Ann Oncol; 2001; 12 Suppl 2():S159-64. PubMed ID: 11762345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma.
    Fixemer T; Remberger K; Bonkhoff H
    Prostate; 2002 Oct; 53(2):118-23. PubMed ID: 12242726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraductal carcinoma of the prostate in the ejaculatory duct.
    Sanchez-Salazar AJ; Basler JW; Nicolas MM
    Int J Surg Pathol; 2010 Aug; 18(4):298-9. PubMed ID: 20444733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
    May M; Siegsmund M; Hammermann F; Loy V; Gunia S
    Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroendocrine cells in pancreatic duct adenocarcinoma: an immunohistochemical study.
    Linder S; Myrvold K; Falkmer UG; Qvigstad G; Waldum HL; Falkmer SE
    J Exp Clin Cancer Res; 2006 Jun; 25(2):213-21. PubMed ID: 16918133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical and ultrastructural features of neuroendocrine differentiated carcinomas of the prostate: an immunoelectron microscopic study.
    Hirano D; Jike T; Okada Y; Minei S; Sugimoto S; Yamaguchi K; Yoshikawa T; Hachiya T; Yoshida T; Takimoto Y
    Ultrastruct Pathol; 2005; 29(5):367-75. PubMed ID: 16257863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The ejaculatory ducts and their implications in prostate adenocarcinoma.
    López JI; Angulo JC
    Anal Quant Cytopathol Histpathol; 2013 Aug; 35(4):205-9. PubMed ID: 24341123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paneth cell-like change in prostatic adenocarcinoma represents neuroendocrine differentiation: report of 30 cases.
    Adlakha H; Bostwick DG
    Hum Pathol; 1994 Feb; 25(2):135-9. PubMed ID: 7509774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells.
    Harper ME; Glynne-Jones E; Goddard L; Thurston VJ; Griffiths K
    Br J Cancer; 1996 Sep; 74(6):910-6. PubMed ID: 8826857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
    Alberti C
    G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue.
    Nakada SY; di Sant'Agnese PA; Moynes RA; Hiipakka RA; Liao S; Cockett AT; Abrahamsson PA
    Cancer Res; 1993 May; 53(9):1967-70. PubMed ID: 8481896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells.
    Bonkhoff H; Stein U; Remberger K
    Hum Pathol; 1995 Feb; 26(2):167-70. PubMed ID: 7532147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity.
    Roudier MP; True LD; Vessella RL; Higano CS
    J Clin Pathol; 2004 Mar; 57(3):321-3. PubMed ID: 14990610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Semen expulsion under the ureterocystoscope].
    Du Q; Wu B; Zou BL; Li ZT; Yang DL; Pan BC
    Zhonghua Nan Ke Xue; 2014 Apr; 20(4):334-7. PubMed ID: 24873160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
    Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
    Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.